Skinvisible announces significant progress in licensee's clinical trials for invisicare formulation targeting nethertons syndrome

Las vegas, nv / accesswire / february 14, 2024 / skinvisible, inc. ("skinvisible") (otcqb:skvi) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, quoin pharmaceuticals, inc. ("quoin") (nasdaq:qnrx). the trials focus on the innovative formulation "qrx003," powered by skinvisible's invisicare® proprietary drug delivery technology, to address the challenges of netherton syndrome ("ns").
QNRX Ratings Summary
QNRX Quant Ranking